IL6 and ovarian cancer: A recent study has shown unequivocally that siltuximab (a monoclonal anti-IL-6 antibody) significantly reduced ovarian cancer expression of STAT3 downstream proteins such as Mcl-1, Bcl-X(L), and survivin, implying proapoptotic effects.